Home > Documents > Biblio - Pubmed

Biblio - Pubmed

Date post: 07-Nov-2014
Category:
Author: tavo-ordonez
View: 131 times
Download: 5 times
Share this document with a friend
Embed Size (px)
Popular Tags:
of 237 /237
21. Acta Trop. 2012 Aug;123(2):117-22. doi: 10.1016/j.actatropica.2012.04.010. Epub 2012 Apr 28. ITN protection, MSP1 antibody levels and malaria episodes in young children of rural Burkina Faso. Kynast-Wolf G, Wakilzadeh W, Coulibaly B, Schnitzler P, Traoré C, Becher H, Müller O. Institute of Public Health, Ruprecht-Karls-University Heidelberg, Germany. [email protected] Malaria blood-stage vaccines are in an early phase of clinical development with MSP1 being a major antigen candidate. There are limited data on the protective efficacy of antibodies against subunits of MSP1 in the malaria endemic areas of sub-Saharan Africa. This prospective cohort study was nested into a large insecticide-treated mosquito net (ITN) trial during which neonates were individually randomised to ITN protection from birth vs. protection from month six onwards in rural Burkina Faso. A sub sample of 120 children from three villages was followed for 10 months with six measurements of MSP1(42) antibodies (ELISA based on recombinant 42kDa fragment) and daily assessment of malaria episodes. Time to the next malaria episode was determined in relation to MSP1(42) antibody titres. MSP1(42) antibody titres were dependent on age, season, ITN-group, number of previous malaria episodes and parasitaemia. There were no significant differences in time until the next malaria episode in children with low compared to children with high MSP1(42) antibody titres at any point in time (101 vs. 97 days in May, p=0.6; 58 vs. 84 days in September, p=0.3; 144 vs. 161 days in March, p=0.5). The findings of this study support the short-lived nature of the humoral immune response in infants of malaria endemic areas. The study
Transcript

21. Acta Trop. 2012 Aug;123(2):117-22. doi: 10.1016/j.actatropica.2012.04.010. Epub 2012 Apr 28. ITN protection, MSP1 antibody levels and malaria episodes in young children of rural Burkina Faso. Kynast-Wolf G, Wakilzadeh W, Coulibaly B, Schnitzler P, Traor C, Becher H, Mller O. Institute of Public Health, Ruprecht-Karls-University Heidelberg, Germany. [email protected] Malaria blood-stage vaccines are in an early phase of clinical development with MSP1 being a major antigen candidate. There are limited data on the protective efficacy of antibodies against subunits of MSP1 in the malaria endemic areas of sub-Saharan Africa. This prospective cohort study was nested into a large insecticide-treated mosquito net (ITN) trial during which neonates were individually randomised to ITN protection from birth vs. protection from month six onwards in rural Burkina Faso. A sub sample of 120 children from three villages was followed for 10 months with six measurements of MSP1(42) antibodies (ELISA based on recombinant 42kDa fragment) and daily assessment of malaria episodes. Time to the next malaria episode was determined in relation to MSP1(42) antibody titres. MSP1(42) antibody titres were dependent on age, season, ITN-group, number of previous malaria episodes and parasitaemia. There were no significant differences in time until the next malaria episode in children with low compared to children with high MSP1(42) antibody titres at any point in time (101 vs. 97 days in May, p=0.6; 58 vs. 84 days in September, p=0.3; 144 vs. 161 days in March, p=0.5). The findings of this study support the short-lived nature of the humoral immune response in infants of malaria endemic areas. The study provides no evidence for antibodies against a subunit of MSP1 being protective against new malaria episodes in infants. Copyright 2012 Elsevier B.V. All rights reserved. PMID: 22569564 [PubMed - indexed for MEDLINE]

22. BMC Public Health. 2012 May 22;12:315. doi: 10.1186/1471-2458-12-315.

Examining equity in access to long-lasting insecticide nets and artemisinin-based combination therapy in Anambra State, Nigeria. Mbachu CO, Onwujekwe OE, Uzochukwu BS, Uchegbu E, Oranuba J, Ilika AL. Health Policy Research Group, Department of Pharmacology and Therapeutics, College of Medicine, University of Nigeria, and Department of Community Medicine, University of Nigeria Teaching Hospital, Enugu, Enugu State, Nigeria. [email protected] BACKGROUND: In order to achieve universal health coverage, the government of Anambra State, southeast Nigeria has distributed free Long-lasting Insecticide treated Nets (LLINs) to the general population and delivered free Artemisinin-based Combination Therapy (ACT) to pregnant women and children less than 5 years. However, the levels of coverage with LLINS and ACTs is not clear, especially coverage of different socio-economic status (SES) population groups. This study was carried out to determine the level of coverage and access to LLINs and ACTs amongst different SES groups. METHODS: A questionnaire was used to collect data from randomly selected households in 19 local government areas of the State. Selected households had a pregnant woman and/or a child less than 5 years. The lot quality assurance sampling (LQAS) methodology was used in sampling. The questionnaire explored the availability and utilization of LLINs and ACTs from 2394 households. An asset-based SES index was used to examine the level of access of LLINS and ACTs to different SES quintiles. RESULTS: It was found that 80.5% of the households had an LLIN and 64.4% of the households stated that they actually used the nets the previous night. The findings showed that 42.3% of pregnant women who had fever within the past month received ACTs, while 37.5% of children


Recommended